No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALC240621P90000
- 2.00
- -0.20-9.09%
15min DelayClose May 31 16:00 ET
2.00High1.55Low
1.55Open2.20Pre Close17 Volume201 Open Interest90.00Strike Price3.36KTurnover18.04%IV-1.07%PremiumJun 21, 2024Expiry Date0.87Intrinsic Value100Multiplier19DDays to Expiry1.13Time Value100Contract SizeAmericanOptions Type-0.5669Delta0.1106Gamma48.84Leverage Ratio-0.0321Theta-0.0215Rho-27.69Eff Leverage0.0796Vega
Intraday
- 5D
- 1D
News
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to Its Board of Directors and Scientific Advisory Board
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D.,
Switzerland's Alcon Launches Middle East Headquarters in Saudi Arabia
Geneva, Switzerland-based Alcon (ALC.SW) formally opened its Middle East headquarters in Jeddah, Saudi Arabia, according to a Tuesday release. The Swiss company said its Jeddah headquarters allows the
Form 144 | Alcon(ALC.US) Officer Proposes to Sell 268.63K in Common Stocks
SEC FILLINGS DISCLOSED/ May 24, $Alcon(ALC.US)$ Officer Attias Laurent intends to sell 3,000 shares of its common stock on May 24, with a total market value of approximately $268.63K. Attias Laurent
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
UBS Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $100.56
UBS analyst Graham Doyle maintains $Alcon(ALC.US)$ with a buy rating, and adjusts the target price from $95.46 to $100.56.According to TipRanks data, the analyst has a success rate of 42.9% and a tota
Top Gap Ups and Downs on Wednesday: ADI, TJX, SCCO and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Comments
$Alcon(ALC.US$ we broke out of that weekly resistance 89.43, lets see if we can continue to 90.66/90.94
$Alcon(ALC.US$
interesting setup. if we are able to break 89.43, we could see 90.66 / 90.44 and 91.88+. Reject 89.43 could take this down to 88.21 / 88.49 and maybe 86.98
interesting setup. if we are able to break 89.43, we could see 90.66 / 90.44 and 91.88+. Reject 89.43 could take this down to 88.21 / 88.49 and maybe 86.98
5
Baird advocates medtech companies such as Alcon, Stryker, and Cooper due to product and pricing strengths. Belief is strong in Alcon's 2024 margin possibilities, Stryker's premium pricing and predicted robust orthopedic demand, and projected revenue growth for Boston Scientific and Axonics.
Gapping up
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
11
Exact Sciences Price Target Raised to $85.00/Share From $55.00 by Craig-Hallum
$Exact Sciences(EXAS.US$ Price Target Raised to $85.00/Share From $55.00 by Craig-Hallum.
Baird Upgrades Alcon to Outperform, Raises Price Target to $90
Baird analyst Jeff Johnson upgrades $Alcon(ALC.US$ from Neutral to Outperform and raises the price target from $75 to $90.
BofA Securities Upgrades Celsius Holdings to Buy, Raises Price Target to $125
B o...
$Exact Sciences(EXAS.US$ Price Target Raised to $85.00/Share From $55.00 by Craig-Hallum.
Baird Upgrades Alcon to Outperform, Raises Price Target to $90
Baird analyst Jeff Johnson upgrades $Alcon(ALC.US$ from Neutral to Outperform and raises the price target from $75 to $90.
BofA Securities Upgrades Celsius Holdings to Buy, Raises Price Target to $125
B o...
15
Read more